Sign In

Sadik Kassim

Experienced Chief Technology Officer in Genomic Medicines

Sadik Kassim serves as the Chief Scientific Officer and Chief Technology Officer (Genomic Medicines) at Danaher Corporation, a role he has held since December 2021. In this capacity, he is responsible for developing platform R&D strategies for genomic medicines and overseeing their implementation across various Danaher operating companies. He also leads scientific and technical diligence efforts related to external R&D collaborations, venture investments, and mergers and acquisitions in the genomic medicine space.1

Education and Background

Kassim completed his PhD in viral immunology, focusing on the innate immune response to herpes simplex virus type 1 and influenza virus. His academic background provides a strong foundation for his work in biotechnology and genomic medicine.1

Previous Experience

Before joining Danaher, Kassim held several significant positions:

  • Chief Technology Officer at Vor Biopharma (October 2019 - December 2021): He led technical operations for the manufacture of CRISPR gene-edited hematopoietic stem cells and CAR-T cell therapies.
  • Executive Director of Process Design at Kite Pharma (January 2019 - September 2019): He managed a team responsible for designing manufacturing processes for CAR and TCR-based therapies.
  • Chief Scientific Officer at Mustang Bio (March 2018 - January 2019): He developed high-throughput analytical assays for gene-modified T cell therapy products aimed at cancer immunotherapy.1

Current Roles

In addition to his role at Danaher, Kassim also serves as an advisor to RA Capital Management, where he provides insights on opportunities in cell and gene therapy.1

Highlights

Aug 15 · linkedin

Mark your calendars: September 13! Integrated DNA Technologies will be hosting its first ever "Synthetic Biology Leadership Seminar" in the heart of Kendall Square at the MassBio Conference Center. Vanessa Almendro, PhD, MBA 🟦, Sandy Ottensmann and I will moderate an all-star lineup of speakers from Harvard University, Harvard Medical School and Massachusetts Institute of Technology including Sangeeta Bhatia, Pamela Silver, Ron Weiss and Daniel G. Anderson (MIT). Space is limited, lunch and networking event afterward, admission is free.....please go here to sign up:

May 14 · linkedin

Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and have become a critical component in the treatment of B-cell malignancies.

However, access remains poor with less than 2% of U.S. hospitals having infrastructure, expertise, and experience to be able to offer these treatments. Globally, only 9% of countries have access to these therapies.

What if more patients could receive cell therapies?   At this year's ISCT, International Society for Cell & Gene Therapy meeting in the City of Vancouver my Cytiva colleagues will introduce a new platform that addresses the key challenges to manufacturing autologous CAR T therapies at commercial scale.

There is an exciting lineup of programs and speakers featuring experts from Allogene Therapeutics, Cytiva, Genentech, and OmniaBio including Timothy Moore, Mitchel Sivilotti, David Shaw, Neil Blackburn, Emmanuel Abate, George White, Aaron Dulgar-Tulloch, Marine de Lageneste, Ph.D, Angela Johnson, Federico Franchi, Stephanie Bourin, Bertrand Foucaut, Martin Westberg, Mojtaba Parvizi, Scott Ripley, Samuel C., Meenakshi Swaminathan, Robert Young, Stella (Che Ryn) Park, and me. Be sure to check it out!   For all the ways you can connect with Cytiva, a Danaher company, at ISCT:

https://lnkd.in/eDWv47Ke

Related Questions

What are some of the key projects Sadik Kassim has led at Danaher Corporation?
How did Sadik Kassim's work at Vor Biopharma impact the field of gene therapy?
What are Sadik Kassim's main responsibilities as Chief Technology Officer at Danaher Corporation?
Can you provide examples of Sadik Kassim's contributions to RA Capital Management?
What is Sadik Kassim's background in viral immunology?
Sadik Kassim
Sadik Kassim, photo 1
Sadik Kassim, photo 2
Add to my network

Experience

Chief Technology Officer (Genomic Medicines) at Danaher Corporation (December 2021 - Present)
Advisor at RA Capital Management, L.P. (December 2021 - Present), Chief Technology Officer at Vor Biopharma (October 2019 - December 2021), Postdoctoral Research Fellow at Gene Therapy Program, University of Pennsylvania (August 2007 - January 2011)

Education

PhD in Microbiology and Immunology from Louisiana State University (2002 - 2007); BS in Cell/Cellular and Molecular Biology from Tulane University (1998 - 2002)

Location

Boston, Massachusetts, United States